Home > Haematology > EHA 2019 > Lymphoid Malignancies > Unmutated IGHV as predictive factor for venetoclax/obinutuzumab benefit in frontline CLL

Unmutated IGHV as predictive factor for venetoclax/obinutuzumab benefit in frontline CLL

Presented By
Dr Eugen Tausch, University of Ulm, Germany
Conference
EHA 2019
Trial
CLL14
Findings from an analysis of genetic aberrations and mutations in patients with chronic lymphocytic leukaemia (CLL) participating in the CLL14 trial were presented by Dr Eugen Tausch (University of Ulm, Germany) [1]. Although both del(17p) and TP53 mutations remain adverse prognostic factors for progression-free survival (PFS) with venetoclax/obinutuzumab treatment, unmutated IGHV was associated with a 3.5-fold improvement in patient response. Dr Tausch explained: “Genomic aberrations, IGHV mutation status and mutations in genes such as TP53 are established prognostic factors in CLL in the context of chemoimmunotherapy. Their role is less‐well established when using chemotherapy-free treatments.” In summary, the CLL14 trial (n=432) showed that the venetoclax combination reduced the risk of disease progression or death by 65% vs obinutuzum...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on